Company Overview
COMPASS Pathways plc operates as a biotechnology company dedicated to advancing mental health treatments within the United Kingdom and the United States markets. The firm's primary focus involves the development of COMP360, a psilocybin therapy currently undergoing Phase III clinical trials for the treatment of treatment-resistant depression, alongside ongoing Phase II clinical trials. This entity functions within the Healthcare sector, specifically categorized under the Medical Care Facilities industry, where it aims to provide novel therapeutic interventions for severe psychiatric conditions. With a market capitalization of $637.97M, the company holds a significant position in the biotech landscape, although it does not report disclosed annual revenue or employee count figures in the available data. The valuation indicates a substantial market interest in the company's pipeline assets, suggesting that investors view the potential approval and commercialization of its psilocybin therapy as a critical driver of future enterprise value.
Financial Health
The company reports a net income of $-287,862,016 for the trailing twelve months, while its EBITDA stands at $-175,074,000, and revenue is not disclosed. The substantial negative gap between the reported net income and EBITDA reveals a heavy cost structure driven by significant non-operating expenses or other comprehensive income/loss items that depress net income well below operating earnings. Despite these losses, the company maintains a free cash flow of $83.55M, which provides a crucial buffer for financial flexibility, allowing the firm to fund its clinical trial programs without immediate external capital raises. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company is not yet profitable and that its revenue generation does not currently cover its direct costs or operating expenses in a way that yields a positive percentage return. The balance sheet holds $149.61M in cash against $35.03M in debt, creating a net cash position, although the debt-to-equity ratio is not available due to negative equity. The current ratio of 0.77 suggests that the company's short-term assets are insufficient to cover its short-term liabilities, pointing to potential liquidity constraints in the immediate term. Furthermore, the return on equity is -565.3% and the return on assets is -51.7%, metrics that reflect the current inability to generate positive returns on the capital base, likely due to the heavy investment phase of the clinical development cycle.
Valuation Assessment
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed at -4.70, a negative figure that implies the market is pricing in future profitability rather than historical earnings. The price-to-book ratio is -10.22, indicating that the market capitalization is valued significantly below the book value of equity, a common characteristic for biotechnology firms with high intangible assets and negative earnings. The price-to-sales ratio is not available, and the EV/EBITDA stands at -3.48, suggesting that valuation is not being driven by traditional earnings multiples but rather by pipeline potential and cash reserves. The stock has traded between a 52-week high of $8.90 and a 52-week low of $2.25, with the current price situated within this volatility range. The beta is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market index based on the provided data. These alternative valuation metrics highlight that the company is being assessed primarily on its clinical trial progress and potential regulatory approvals rather than established financial performance.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of earnings growth speed relative to revenue expansion. Since the company is not a dividend payer, the dividend yield is not available and the payout ratio is 0.0%, meaning the firm reinvests all available capital and earnings into research and development rather than distributing income to shareholders. The absence of a dividend payout aligns with the typical lifecycle of a biotechnology company in the clinical trial phase, where capital is prioritized for advancing assets like COMP360. The overall growth and income profile is characterized by a lack of current profitability and dividend distribution, relying instead on the potential future value generation from its mental health therapeutic pipeline.